Russell Investments Group
JANX icon

Russell Investments Group’s Janux Therapeutics JANX Stock Holding History

Russell Investments Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$597K Buy
42,938
+21,876
+104% +$300K ﹤0.01% 2433
2025
Q4 		$291K Buy
21,062
+3,560
+20% +$83.7K ﹤0.01% 2699
2025
Q3 		$428K Sell
17,502
-38,034
-68% -$926K ﹤0.01% 2535
2025
Q2 		$1.28M Sell
55,536
-98,312
-64% -$2.59M ﹤0.01% 1940
2025
Q1 		$4.15M Buy
153,848
+152,837
+15,117% +$5.76M 0.01% 1267
2024
Q4 		$54.1K Buy
1,011
+442
+78% +$23.4K ﹤0.01% 2805
2024
Q3 		$25.8K Sell
569
-460
-45% -$20K ﹤0.01% 2909
2024
Q2 		$43.1K Buy
1,029
+1,018
+9,255% +$47.8K ﹤0.01% 2798
2024
Q1 		$414 Buy
+11
New +$240 ﹤0.01% 3231
2023
Q3 		– Sell
-1,532
Closed -$18.2K – 3572
2023
Q2 		$18.2K Hold
1,532
– – ﹤0.01% 2856
2023
Q1 		$18.5K Buy
+1,532
New +$25.5K ﹤0.01% 2824

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Russell Investments Group's JANX Position: Q1 2026 in Review

Russell Investments Group increased its Janux Therapeutics (JANX) stake by 104% in Q1 2026, buying an estimated $300K and bringing the position to 42,938 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #2433.

Russell Investments Group first reported a position in JANX in Q1 2023 and has held it in 11 quarters since. The position peaked at $4.15M in Q1 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Russell Investments Group held 42,938 shares of Janux Therapeutics worth $597K as of Q1 2026.
  • Russell Investments Group bought 21,876 Janux Therapeutics shares in Q1 2026, an estimated $300K.
  • Janux Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2433 holding.
  • Russell Investments Group first reported a position in Janux Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Russell Investments Group's Janux Therapeutics position peaked at $4.15M in Q1 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.